Abbott Laboratories $ABT Shares Sold by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 44.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,302 shares of the healthcare product maker’s stock after selling 5,735 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Abbott Laboratories were worth $663,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. J. Stern & Co. LLP increased its position in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $2,938,892,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Abbott Laboratories by 217.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after acquiring an additional 3,780,402 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after purchasing an additional 3,330,368 shares during the period. Finally, Ninety One UK Ltd acquired a new stake in Abbott Laboratories in the 4th quarter valued at approximately $336,815,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $109.70 on Wednesday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market capitalization of $189.82 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 2.10 and a beta of 0.59. The business’s fifty day moving average price is $96.38 and its 200 day moving average price is $99.71.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the firm posted $1.26 EPS. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABT. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Argus lowered their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.